GSK to Close Dresden Vaccine Factory as 641 German Manufacturing Jobs Face Risk

Germany's manufacturing squeeze is reaching pharmaceuticals as well as autos and chemicals. GSK plans to close its vaccine factory in Dresden in the summer of 2027, putting 641 jobs at risk according to the IGBCE trade union.

The reason is not simply weak German demand. GSK says demand is declining for traditional egg-based influenza vaccines, the production technology associated with the Dresden site.

Vaccine technology is changing the economics of legacy plants

Egg-based flu vaccines require a specialised production system developed over decades. Newer cell-based and recombinant approaches can alter development timelines, manufacturing flexibility and the way producers respond to circulating strains.

That creates the same challenge seen in other industrial sectors: a technically capable plant can become economically vulnerable when the product architecture around it changes. The question for Dresden is whether alternative production can be brought to the site or whether the fixed infrastructure is too specialised.

Our view: Germany's industrial transition is broader than heavy manufacturing

German Business Review's view is that the Dresden closure belongs in the wider debate about industrial renewal. Germany's competitiveness problem is not only about electricity-intensive factories. It is also about whether established sites can attract the next generation of products before older technologies lose demand.

The next checkpoints are consultation with employees, any buyer or reuse process for the site and whether Saxony can replace the lost activity with newer life-sciences manufacturing.